T-cell engagers and antibody-drug conjugates are expanding the SCLC treatment landscape as researchers focus on improving responses and overcoming resistance.
Triparna Sen
Advertisement
Triparna Sen, PhD, is a professor and associate director of research in the Division of Medical Oncology, Department of Internal Medicine, at The Ohio State University. Her research focuses on small cell lung cancer biology and the development of new therapeutic strategies.
Articles by Triparna Sen
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
FDA Approves BESREMi for Essential Thrombocythemia, Expanding Treatment Options
2
Weight-Loss Medication Helps Some Breast Cancer Survivors Reach 5% Goal
3
The Long Game: Living When Cancer Doesn't Go Away
4
FDA Approves Mimrylo for Polycythemia Vera, Offering a New Treatment Approach
5